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Grand Forks, ND 58202-9037

Abstract
• Asthma: a heterogeneous disease characterized by chronic
airway inflammation resulting in respiratory difficulty.
• Bronchial Thermoplasty (BT): a bronchoscopy procedure that
delivers radiofrequency energy to the tissues of airway walls
thus heating the tissue, causing ablation to reduce the mass
of the airway smooth muscle (ASM), hence attenuating
bronchoconstriction.
• BT was designed to decrease, de-bulk or partially eliminate
excess smooth muscle tissue in the distal airways, with a
subsequent decrease in the number of severe asthma
attacks.
• BT is an alternative treatment for patients with severe,
uncontrolled asthma in which the airway smooth muscle is
eliminated using radio ablation.
• In this project, several studies are presented to demonstrate
the effectiveness and potential adverse impacts of BT.
• Special attention to a study performed to evaluate the safety
and the effectiveness of BT in 580 asthma patients across 6
nations with symptoms despite being treated with high doses
of Inhaled corticosteroid (ICS) and long acting beta agonist
(LABA), the current standard of care for severe asthma.

Introduction
• Asthma is the fourth leading cause of absence from work for
adults, resulting in approximately 15 million missed or less
productive workdays each year
• Severe asthma includes a multitude of heterogeneous group
of phenotypes rather than one disease entity.
• Treatment for severe uncontrolled asthma is concentrated
on tailoring to specific phenotypes driven by the endotypes.
• Per American Thoracic Society guidelines, severe asthma
requires management with high-dose inhaled corticosteroids
in addition to a second asthma controller, including potential
utilization of systemic corticosteroids.
• Advances in treatment in the past six years have now
provided us with new plans to modulate the airway smooth
muscle with BT.

Statement of the Problem
• High-cost ER bills for patients with uncontrolled asthma
• Some hospital administrators & pharmacy directors choose
medications based on pricing, not on efficiency of treatment.
• Studies are needed to show the effectiveness and impact of
Bronchial Thermoplasty in severe asthma patients and
qualifications for it.

Research Question
• What is the effectiveness and safety of the Bronchial
Thermoplasty procedure on Asthma patients?
• What are the criteria to be qualified for Bronchial
Thermoplasty in patients with severe asthma?

Literature Review
Pathophysiology of BT
• Contractility of the airway smooth muscle is governed by
pacemakers within the proximal airways, and when the
thermoplasty ablates these pacemakers, the distal airway
constriction relaxes.
• There also may be a phenotype of patients whose asthma is
more likely to be characterized by large airway inflammation
and obstruction, making these patients better candidates for
benefiting from BT.
Safety & Effectiveness of BT
• AIR2 Trial Study: A multi-center, randomized, double-blind,
sham-controlled trial with 297 patients with severe asthma
despite being managed by ICS and LABA
• 32% reduction in severe exacerbations, 84% reduction in
number of ER visits for respiratory symptoms, and 66%
reduction in time lost from work, school and other daily
activities as the result of asthma.

Discussion
• Patients treated with BT had only 0.19 points enhancement
in AQLQ scores (1.35 vs. 1.16 with sham procedure), falling
well short of the cutoff of 0.5 points for a “clinically
meaningful” improvement in the AQLQ over the sham group
• Patients treated with BT had significantly fewer emergency
room visits, reduced exacerbations, and fewer days missed
from school or work
• Both the sham and BT groups exhibited clinically significant
AQLQ improvement, raising the question that it may have
been the perception of undergoing an invasive procedure
that led to the patient-perceived benefits. The authors cited
no reported differences in FEV1, peak flow, or rescue
medication usage between the sham and treatment groups.
• Treated subjects who were already taking high doses of ICS
and LABA were found to have a similar magnitude of
improvement when compared to subjects in previous
asthma studies taking less medication.
• Additional long-term clinical trials are needed to approve the
benefits of BT
• AIR2 trial criticized for its method to patient selection Patients with more severe asthma (low FEV1, greater than 2
exacerbations or pneumonias in the previous year, or greater
than 3 oral steroid bursts in the previous year) were
excluded from the study, raising doubts on extending the
benefits of Bronchial Thermoplasty to such patients

Applicability to Clinical
Practice
• Minimally invasive procedure
• Per the Global Initiative for Asthma, BT may be considered
for patients with uncontrolled asthma, whose symptoms
remain severe despite treatment with drug-based regimens
• ACAAI recommends that insurers provide coverage for
Bronchial Thermoplasty for those adult patients who meet
the strict requirements
• BT is not expected to be done on individuals who have a
known allergy to atropine, benzodiazepines, and lidocaine;
neither is it suggested for those with a pacemaker,
implantable cardioverter defibrillator or other implantable
electronic devices
• Three treatment periods with approximately 3-week
intervals are suggested: first session involves the right lower
lobe; the second session targets the left lower lobe; the third
session follows with both upper lobe
• Each bronchus is treated along its entire visible length - No
area should be treated more than once
• tremendously impacted the government financials and
significantly reduced expenses associated with the
emergency room – covered by Medicaid
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• 3 months of BT significantly decreased autonomic nerve
fibers of the parasympathetic system leading to reduction in
the number of severe asthmatic symptoms
• Reduction of airway structural abnormalities and the
reduction of neuroendocrine epithelial cells.

•

• Thickening of submucosal nerves and the SBM

•

Cost Effectiveness of BT

•

• Markov model: sensitivity to the cost of the Bronchial
Thermoplasty procedure and to the rate of
hospitalizations.
• Patients who had one or more hospitalizations within a
year, using Bronchial Thermoplasty would be costeffective at US$5500/QALY
• Financial savings can be observed three to four years
after initiating the Bronchial Thermoplasty procedure in
patients who are either Omalizumab non-responders or
on corticosteroids who were contraindicated for
Omalizumab.
• In patients with moderate-to-severe allergic asthma, there
is more than a 60% chance that BT compared to
Omalizumab and standard therapy becomes costeffective at the patients willingness to pay (WTP) of
$100,000/QALY
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